|
Mr. Auerbach joined Cougar Biotechnology Inc. in May 2003 as Chief Executive Officer and President. From June 1998 to April 2003 Mr. Auerbach was Vice President Senior Research Analyst at Wells Fargo Securities where he was responsible for research coverage of small and middle capitalization biotechnology companies with a focus on companies in the field of oncology. He had primary responsibility for technical scientific and clinical due diligence as well as selection of biotechnology companies followed by Wells Fargo Securities. During 2002 Mr. Auerbach ranked second in the NASDAQ/Starmine survey of analyst performance for stock picking in biotechnology. From August 1997 to May 1998 Mr. Auerbach was Vice President Research Analyst at the Seidler Companies Inc. where he was responsible for research coverage of small capitalization biotechnology companies. Prior to his work as a biotechnology analyst Mr. Auerbach worked for Diagnostic Products Corporation where he designed and implemented clinical trials in the field of oncology.
Mr. Auerbach received his B.S. in biomedical engineering from Boston University and his M.S. in biomedical engineering from the University of Southern California. | 